The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria-targeting cardiolipin peroxidation inhibitors. Visomitin® has reached Phase III in the U.S. for dry eye disease. Visomitin’s mechanism of action addresses the most important clinical needs in dry eye disease: tear quality, cornea/conjunctiva healing rate and inflammation.

With an established safety profile and extensive mechanistic evidence, Mitotech is preparing for the clinical development of Visotmitin in other ophthalmic indications, notably glaucoma, Leber’s Hereditary Optic Neuropathy (LHON), dry AMD, and uveitis.

Pipeline

Drug/Indication
 
Pre-clinical
Phase 1
Phase 2
Phase 3

Visomitin® (SkQ1 eye drops)

Dry Eye
Phase III
Glaucoma
Phase II ready
Uveitis
Phase II ready
Dry AMD
Phase II ready
LHON
Phase II ready